PCLO — Pharmacielo Income Statement
0.000.00%
- CA$8.46m
- CA$30.64m
- CA$3.97m
- 14
- 35
- 18
- 10
Annual income statement for Pharmacielo, fiscal year end - March 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | C2022 December 31st | 2023 December 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 15 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 2.65 | 1.95 | 5.31 | 1.54 | 3.97 |
| Cost of Revenue | |||||
| Gross Profit | -5.04 | -3.07 | 1.59 | -1.88 | 0.828 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 47.3 | 27.1 | 18 | 15.4 | 11.1 |
| Operating Profit | -44.6 | -25.2 | -12.7 | -13.9 | -7.17 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -43.8 | -26.6 | -14.5 | -16.3 | -11.4 |
| Net Income After Taxes | -43.8 | -26.6 | -14.5 | -16.3 | -11.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -43.8 | -26.6 | -14.5 | -16.3 | -11.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -43.8 | -26.6 | -14.5 | -16.3 | -11.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.363 | -0.174 | -0.082 | -0.081 | -0.057 |
| Dividends per Share |